Advances in Molecular Oncology and Therapeutics
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 414
Special Issue Editors
Interests: genomic stability; DNA repair; cancer biology; cancer therapeutics
Special Issue Information
Dear Colleagues,
Advances in precision medicine and molecular oncology have revolutionized cancer treatment by tailoring therapies to match each individual patients’ unique tumour profile. Underpinning this, is precision medicines use of cutting-edge technologies to create and integrate omic profiles (including genomic, transcriptomic, proteomic, immunological, metabolomic) to identify clinically relevant biomarkers. These molecular profiles facilitate optimized personalized treatment strategies, enhancing therapeutic options and minimizing unnecessary side effects.
Molecular oncology has seen significant advancements in our understanding of the molecular mechanisms underpinning cancer biology. Identification of genetic mutations, dysregulated expression patterns of proteins, genes and microRNA, and improved understanding of how these changes alter the signalling pathways involved in tumour initiation, progression, and resistance to treatment, has led to the development of targeted therapies. Targeted therapies are designed to specifically target the changes responsible for cancer cell survival, proliferation and therapeutic resistance.
Aiding this, novel diagnostic tools have emerged, including liquid biopsies and next-generation sequencing techniques, enabling non-invasive and/or comprehensive profiling of tumour profiles (transcriptomic, genomic and epigenetic). This profiling facilitates early detection of cancer and monitoring of treatment response, which can be used to inform therapeutic regimens.
There has been significant recent advances in the molecular understanding and development of novel cancer therapeutics. For this special issue, we are interested in publishing the latest research in molecular oncology, and advances in the areas related to therapeutics, including the development of new drugs and improved understanding of the mechanism of action of current therapeutics or the investigation of therapeutic resistance mechanisms.
In this Special Issue, original research articles and review articles are welcome. Research areas may include (but are not limited to) the following:
- Cancer Biomarkers;
- Molecular Oncology;
- Cancer therapeutics;
- Mechanisms of therapeutic resistance;
- Anti-cancer drug development and characterisation.
We look forward to receiving your contributions.
Dr. Amila M. Suraweera
Dr. James A.L. Brown
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- oncology
- therapeutics
- signalling
- genome instability
- treatment
